Přihlásit se Zaregistrujte se zdarma

Last updated: 12 June 2024 at 8:20pm EST

Gregory Perry Net Worth




The estimated Net Worth of Gregory D Perry is at least $245 Tisíc dollars as of 10 September 2013. Mr. Perry owns over 18,337 units of Kala Bio stock worth over $110,389 and over the last 16 years he sold KALA stock worth over $0. In addition, he makes $134,972 as Independent Director at Kala Bio.

Mr. Perry KALA stock SEC Form 4 insiders trading

Gregory has made over 7 trades of the Kala Bio stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 18,337 units of KALA stock worth $79,216 on 10 September 2013.

The largest trade he's ever made was exercising 18,337 units of Kala Bio stock on 10 September 2013 worth over $79,216. On average, Gregory trades about 2,135 units every 48 days since 2009. As of 10 September 2013 he still owns at least 18,337 units of Kala Bio stock.

You can see the complete history of Mr. Perry stock trades at the bottom of the page.





Gregory Perry biography

Gregory D. Perry serves as Independent Director of the Company. Mr. Perry has served as Chief Financial Officer for Finch Therapeutics Group, Inc., a private therapeutics company focused on the microbiome, since June 2018. Previously, he served as Chief Financial and Administrative Officer of Novelion Therapeutics Inc., or Novelion, a public biopharmaceutical company, from November 2016 to December 2017. Prior to this, Mr. Perry was Chief Financial Officer of Aegerion Pharmaceuticals Inc, a public biopharmaceutical company, from July 2015 until its merger with Novelion in November 2016. Prior to that, he served as Chief Financial and Business Officer of Eleven Biotherapeutics, Inc., a public company, from January 2014 to June 2015. Before joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics, a public biotechnology company, from September 2013 to December 2013, and prior to that he served as the Senior Vice President and Chief Financial Officer of ImmunoGen, Inc., a public biotechnology company, from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role he held until 2013. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr. Perry previously was Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Since May 2016, Mr. Perry has served on the board of directors of Merus N.V., a public clinical-stage immuno-oncology company, including as Chair of its Audit Committee. From December 2011 to February 2016, Mr. Perry served on the board of directors of Ocata Therapeutics, a public biotechnology company, including as Chair of its Audit Committee and a member of its Compensation Committee, until it was acquired by Astellas Pharma Inc.

What is the salary of Gregory Perry?

As the Independent Director of Kala Bio, the total compensation of Gregory Perry at Kala Bio is $134,972. There are 9 executives at Kala Bio getting paid more, with Mark Iwicki having the highest compensation of $2,556,170.



How old is Gregory Perry?

Gregory Perry is 59, he's been the Independent Director of Kala Bio since 2018. There are 4 older and 14 younger executives at Kala Bio. The oldest executive at Kala Bio Inc. is Dr. Kim Brazzell Ph.D., 68, who is the Head of R&D and Chief Medical Officer.

What's Gregory Perry's mailing address?

Gregory's mailing address filed with the SEC is C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476.

Insiders trading at Kala Bio

Over the last 7 years, insiders at Kala Bio have traded over $2,579,128 worth of Kala Bio stock and bought 23,705,318 units worth $209,975,371 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ... a Rajeev M. Shah. On average, Kala Bio executives and independent directors trade stock every 31 days with the average trade being worth of $2,090,132. The most recent stock trade was executed by Todd Bazemore on 26 June 2024, trading 4,653 units of KALA stock currently worth $22,102.



What does Kala Bio do?

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.



What does Kala Bio's logo look like?

Kala Bio Inc. logo

Complete history of Mr. Perry stock trades at Immunogen, InVivo Therapeutics Corp, Merus N.V a Kala Bio

Datum
#
Společnost
 Osoba
Trans.
Transakce
 Počet akcií Cena za akcii Celková cena Počet akcií po Zdroj
10 Sep 2013 IMGN Immunogen, Inc. Gregory D Perry
Finanční ředitel
 Využití opce 18,337 $4.32 $79,216
10 Sep 2013
18,337 ↗
15 Nov 2011 IMGN Immunogen, Inc. Gregory D Perry
Finanční ředitel
 Využití opce 8,333 $4.32 $35,999
15 Nov 2011
8,333 ↗
17 Oct 2011 IMGN Immunogen, Inc. Gregory D Perry
Finanční ředitel
 Využití opce 8,333 $4.32 $35,999
17 Oct 2011
8,333 ↗
26 Sep 2011 IMGN Immunogen, Inc. Gregory D Perry
Finanční ředitel
 Využití opce 8,333 $4.32 $35,999
26 Sep 2011
8,333 ↗
15 Aug 2011 IMGN Immunogen, Inc. Gregory D Perry
Finanční ředitel
 Využití opce 8,333 $4.32 $35,999
15 Aug 2011
8,333 ↗
15 Jul 2011 IMGN Immunogen, Inc. Gregory D Perry
Finanční ředitel
 Využití opce 8,333 $4.32 $35,999
15 Jul 2011
8,333 ↗
29 Jun 2009 IMGN Immunogen, Inc. Gregory D Perry
Finanční ředitel
 Využití opce 8,333 $4.32 $35,999
29 Jun 2009
8,333 ↗


Kala Bio executives and stock owners

Kala Bio executives and other stock owners filed with the SEC include: